Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants.
Because of the interference by maternal antibody before 1 year of age, the Schwarz strain of measles vaccine, which has been routinely used in Taiwan, must be given at 9 months and 15 months of age to ensure an optimal immune response. The AIK-C strain of measles vaccine has been reported to be highly immunogenic. This study evaluated the immunogenicity and safety of the AIK-C vaccine in 9-month-old Taiwanese infants. A total of 135 infants were recruited and were randomly assigned to receive either Schwarz vaccine (68 cases) or AIK-C vaccine (67 cases). Measles antibodies were assayed before and 1 month after the vaccination. Sixty-five (97%) infants who received the AIK-C vaccine seroconverted after the vaccination, whereas the seroconversion rate in those receiving the Schwarz vaccine was 77% (P = 0.001). The incidences of adverse reactions were comparable between the two groups. We conclude that even in 1990s, the failure rate of Schwarz vaccine in 9-month-old infants is still high. The AIK-C vaccine is more immunogenic in infants and its long-term immunogenicity and safety deserve further evaluation.
Tsai
H Y
HY
Department of Pediatrics, Taipei Municipal Ho-Ping Hospital, Taiwan.
Huang
L M
LM
Shih
Y T
YT
Chen
J M
JM
Jiang
T M
TM
Tsai
C H
CH
Lee
C Y
CY
D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008457:Measles / Q000517:prevention & control; D008458:Measles Vaccine / Q000009:adverse effects* / Q000276:immunology*; D008459:Measles virus / Q000276:immunology*; D014611:Vaccination
D000914:Antibodies, Viral; D008458:Measles Vaccine